Issuance of 2,932,000 ordinary shares by the 4th third-party allotment (subscription price 119 yen, total 348,900,000 yen), issuance of 29,320 stock acquisition rights (subscription price 117 yen, potential shares 2,932,000 shares, exercise period 2026\/10\/21-2030\/10\/18). Use of proceeds: R&D for GPC-1 CAR-T for refractory solid tumors and related preparation for clinical start. Total funds approximately 818.52644 million yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4978","jir_company_name":"ReproCELL Incorporated","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4978-20261005-01.pdf","jir_short_summary":"Issuance of 2,932,000 ordinary shares by the 4th third-party allotment (subscription price 119 yen, total 348,900,000 yen), issuance of 29,320 stock acquisition rights (subscription price 117 yen, potential shares 2,932,000 shares, exercise period 2026\/10\/21-2030\/10\/18). Use of proceeds: R&D for GPC-1 CAR-T for refractory solid tumors and related preparation for clinical start. Total funds approximately 818.52644 million yen.","jir_summary":"### Overview of Capital Policy\nReproCELL Incorporated, through its stock and stock acquisition rights issuance program, will allot 2,932,000 ordinary shares to CVI Investments, Inc. as the 4th third-party allotment and will also issue the same number of stock acquisition rights. The subscription price is 119 yen for the shares and 117 yen for the rights, and the total funds amount to approximately 819 million yen. The proceeds are planned to be allocated to research and development and preparation for clinical start of the GPC-1 CAR-T therapy targeting refractory solid tumors, among other uses.\n\n### Impact on Shareholders and Future Outlook\nThe 4th allotment will cause dilution; however, it is judged that the purpose and use of the fundraising will contribute to medium- to long-term corporate value, and the increase in total issued shares is considered reasonable. The allottee is CVI Investments, Inc., and conditions related to subscription and exercise rights are ensured as fair based on valuations using methods such as Monte Carlo simulations. Disbursement of funds will be carried out in stages from October 2026 through 2029.","jir_financial_highlights":"Number of newly issued shares: 2,932,000 shares (Unknown)\nTotal number of stock acquisition rights: 29,320 units (Unknown)\nSubscription price (ordinary shares): 119 yen\/share (Unknown)\nAmount of funds to be raised: 818,526,440 yen (Unknown)\nDilution rate: 6.16% (voting rights basis 6.17%) (Change from prior period Unknown)","jir_category":"","jir_hashtags":"#ReproCELL, #CapitalPolicy, #ThirdPartyAllotment, #StockAcquisitionRights","jir_key_figures":"2,932,000 shares: Number of ordinary shares in the 4th third-party allotment\n29,320 units: Total number of stock acquisition rights in the 4th round\nSubscription price: 119 yen\/share, total 348,900,000 yen","jir_meta_title":"ReproCELL Incorporated Announces 4th Allotment Under Stock Issuance Program | October 2026","jir_meta_description":"ReproCELL Incorporated announces the 4th allotment under its stock and stock acquisition rights issuance program. 2,932,000 ordinary shares allotted to CVI Investments at 119 yen\/share, total approximately 818.52644 million yen. Stock acquisition rights offered at 117 yen\/unit; exercise period 2026\/10\/21-2030\/10\/18.","jir_og_title":"ReproCELL Incorporated Announces 4th Allotment Under Stock Issuance Program | October 2026","jir_og_description":"ReproCELL Incorporated will issue 2,932,000 ordinary shares and stock acquisition rights in the 4th third-party allotment. Proceeds will be used for R&D of CAR-T therapeutics and related activities.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58459,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-127552","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n